Alnylam Sheds Legal Trouble But Picks Up Manufacturing Challenge In Tekmira Settlement
This article was originally published in The Pink Sheet Daily
Alnylam is paying Tekmira $65 million to resolve an RNAi trade secrets suit; the new licensing pact reduces Alnylam’s future milestone and royalty payments on three compounds and allows the firm to manufacture its own drug candidates.
You may also be interested in...
RNAi pioneer is getting closer to market with NDA filing in amyloidosis expected in 2017, but ample competition is coming along, albeit far behind.
Building on the 10-pharma clinical development problem-solving initiative launched in September, J&J, Merck and Lilly are spearheading a databank that will share information on clinical trial sites and investigators, with a primary goal of avoiding redundancy in paperwork and training.
RNAi pioneer Alnylam is partnering its transthyretin-mediated amyloidosis program with Genzyme in Japan and Asia-Pacific, while planning to keep rest-of-world rights to the program in-house.